PULLLLLLERALLLLLARM!!!!BIOTECHINDEX ZIEL 500 PUNKTE!!!!!!!!! - 500 Beiträge pro Seite

[scarfaces]

RAUSSSS

[derbayer]

@scarfaces: selten so ne` ausführliche analyse gesehen! du bist profi was?

servus der bayer

p.s.: arbeitest du immer so genau?

[Reppi]

HOFFENTLICH
Bei dieser Super Analyse warte ich noch mit dem einsteigen ein paar tage
mfg (Mit freundlichem Grinsen) Reppi

[bigguru]

Der Amex Biotech Index hat in der zurückliegenden Woche endgültig die langfristige Aufwärtstrend nach unten verlassen. Es hat sich ein gigantisches Doppel Top ausgebildet. Das erste Top in Form eines Peaks, das zweite Top in Form eines Rounding Tops. Nachdem sich der Index recht lange der Korrektur im Nasdaq entziehen konnte und relative Stärke zeigte, hat sich dies nun grundlegend geändert. Man kann sagen, daß der Amex Biotech Index mit sehr hoher
Wahrscheinlichkeit weiter stark korrigieren wird. Das nächste Kursziel liegt bei 380 Punkten.







viel glück...............

[DerStaatsanwalt]

Montag kaufe ich Biotechs bis zum Abwinken.
Medarex, Medarex, Medarex
Millenium, Millenium
VERTEX , VERTEX , VERTEX
Das ist das einzige Segment mit Phantasie

B2B ist aus, Internet und Computer auch-- von hier kommen keinen Neuen Impulse mehr

Lass mal einen Blockbuster gegen Aids oder Krebs kommen,
dann knallt eine Bio Perle durch die Decke.

Montag geht es hoch

[Rudra]

......PULLLLERALLLLARM -NASDAQ 1400 PUNKTE!!!!!!!! 5 scarfaces 17.03.01 19:35:44
PULLLLLLLLERALLLLLLLLLLLLLARM!!TEIL 2!!!NASDAQ-1400 PUNKTE!NEMAX 1000 PUNKTE!!!! 12 scarfaces 17.03.01 19:27:12
PULLLLLLERALLLLLARM!!!!BIOTECHINDEX ZIEL 500 PUNKTE!!!!!!!!!
......sag mal hast du sie noch alle????

[LudwigvanB]

scarface hat das, was zu befürchten ist, zwar sehr kurz dargestellt, aber bigguru hat´s ja noch mal erläutert. Ich denke mal, dass auch der jetztige Abschwung der Bio´s eine Mischung aus Vertrauensschwund + Sicherung noch ev. vorhandener Gewinne ist. War selbst im DWS BIO O drin, bin nach 2 Tagen wieder raus, weil ich die bestimmt noch billiger kriege. So hab´ich gedacht beim Stand von 100 E, beim Stand von 90 E und jetzt bei 80 E. Geht´s mit dem Nasdaq-Comp. bis auf 1750 runter (s. Dazu EW-Analyse von W:O; 16.3./ 14:35:56), wären das 7,5%. Um soviel dürfte auch der Bio-Bereich mind. nochmal fallen - eher aber noch drunter. Deshalb, liber Staatsanwalt, wäre ich mit dem Kauf von Bio´s sehr vorsichtig. Dies sage ich als -wenn überhaupt- immer zu 100% Bio-Investor.
LvB

[LudwigvanB]

Musste heißen:
W:0
lieber
Investierter

[KMS]

So langsam ist die Stimmung richtig schön mies bei den Biotechs.

Nachdem sich auch die aussichtsreichsten Werte (mit mehreren interessanten Produkten in der Pipeline) geviertelt haben, wie z.B. eine MLNM oder PDLI,... kommen wir langsam in eine sehr interessante Phase:

Entweder der gesamte Biotech-Bereich bringt dieses Jahr (fast) keine Medikamente mehr zur Marktreife, dann wird die Biotech-Phantasie erst mal einen Tiefschlaf einlegen, oder aber... dies wird sogar ein weit überdurchschnittliches Jahr -vielleicht ein Rekord-Jahr- was die marktreifen Produktneuerungen betrifft.
Dann wird die Branche wieder boomen.

Alles ist möglich, wobei ich die zweite Variante für wesentlich wahrscheinlicher halte.

MfG
KMS

[LudwigvanB]

@ KMS,
es gibt leider noch eine -wie ich glaube, die wahrscheinlichste- Variante: Es wird marktreife Produkte geben, daneben aber auch nicht erteilte Zulassungen. Das Resultat wird absolute Volatilität des NBX sein - wie im Vorjahr. Und da das m.E. immer in der Bio-Branche so sein wird, bin ich zum dreimal gehörnten Teufel nochmal selbstverständlich in einem Bio-Fonds drin, und zwar in einem, den man wie eine Aktie an der XETRA handeln kann. Es ist der DWS-BIO Typ 0.
Ich war auch mal ein Vertreter der Sorte "Lass doch liegen, die kommen schon wieder". Wenn ich diesem Rat gefolgt wäre, säße ich ich jetzt mit einem Minus im Sessel. Dieser Spruch mag gültig sein, aber nicht in solchen (Phantasie)Segmenten wie der Biotechnologie; jedenfalls jetzt noch nicht (in einigen Jahren schon).
LvB

[KMS]

@LudwigvanB,

natürlich wird es auch nicht erteilte Zulassungen geben. Dies wird aber nur einzelne Biotech-Firmen betreffen, und das kann dann natürlich bei einem Unternehmen, daß evtl. nur 1(-2)Produkte entwickelt, fatal sein. So hat es z.B. eine Maxim Ph. in 2000 fast zerrissen.

Aber noch nie waren so viele neue Biotech-Produkte kurz vor der Marktreife. Da sehe ich die Chancen für eine bisher bei weitem nicht erreichte Vielzahl von erfogreichen Abschlüssen der Phase 3-Testungen für klar überwiedend.

Der Sektor an sich dürfte daher outperformen. Was aber nicht heißt, daß wir jetzt am Boden sind. Das kann niemand sagen.


MfG
KMS

[LudwigvanB]

ich möchte noch hinzufügen, dass mich meine anfängliche Verliebtheit in die Biobranche glücklicherweise nicht blind gemacht hat für die Grausamkeit, mit der auch hier die Kurse ins Bodenlose fallen können. Nie und nimmer !!! sollte man sagen, dass dieser oder jene Wert nicht noch tiefer fallen kann. User Dosto hat das mal so schön kurz (sinngemäß)formuliert: Wenn die Kurse abschmieren, geht man selbstverständlich raus und guckt sich das weiter von der Seite aus an. Man bleibt doch nicht drin, nur weil einem eine Firma sympatisch ist!!
Das mag nach Binsenweisheit klingen, ist im Kern aber eine der Weisheiten, deren Beachtung so manchen vor sehr sehr viel Verzweiflung bewahrt hätte.
Es ist zugegebenermaßen sehr schwer, sich nicht durch andere beeinflussen zu lassen, aber das eigene erste Gefühl für eine Situation ist oft das richtige und sollte dann auch konsequent in "Halten", "Kauf" oder "Verkauf" umgesetzt werden. Wer kennt nicht jemanden, dem es schon im Oktober mulmig wurde und dem die innere Stimme sagte, geh raus, verkaufe. Und was wurde daraus? Man ist drin geblieben, weil "die ja wieder kommen müssen, etc.etc.". Ich bin drin geblieben, weil ich unbedingt die Spekufrist aussitzen wollte. Nie mehr wird mir das passieren!
LvB

[LudwigvanB]

@KMS,
im Grundsatz hast Du wohl recht. Aber bedenke bitte, dass im Falle eines fatalen ! Fehlers einer Firma (z.B. stellt sich raus, dass ein Produkt erst nach 2 Jahren zu Karzinomen führt, was man früher nicht wissen konnte) die gesamte Bio-Branche abschmieren kann. Deshalb handele ich den Bio-Fonds wie eine Aktie mit Stopp/Loss an der XETRA.
mfg
LvB

[KMS]

@LudwigvanB,

Teilweise gebe ich Dir Recht:
Wenn die Kurse völlig überhitzt sind, und selbst die "einfache Putzfrau" -aufgehetzt von der Bildzeitung- in hochspekulative Aktien einsteigt (und dazu gehören sicher auch etliche Biotechs), ist es Zeit, sich zu verabschieden. Diese Phase war vor einem Jahr. Niemals sollte man sich auch in einen Wert "verlieben".

Inzwischen dürften aber v. a. die Profis längst ihre Gewinne realisiert haben. Die Biotech-Fonds sitzen inzwischen auf einer sehr hohen Liquidität. Die Frage ist, wann sie wieder einsteigen. Dies könnte aber sehr bald geschehen. Und geklingelt wird erst, wenn der Sektor schon längst wieder angezogen hat. Dann sollen wir kleinen Privatanleger noch einen Schub drauflegen und schließlich den schon längst viel billiger Investierten ihre Papiere wieder abnehmen.
Da kaufe ich doch lieber billig Biotechs ein, auch auf die Gefahr hin, daß ich ein paar wenige Prozent evtl. noch verliere.
In Standardwerte, die fast kein Gewinn-Wachstum aufweisen, möchte ich jetzt nicht mehr investieren. Da war 2000 besser geeignet.


MfG
KMS

[Dr.Hook]

@KMS

Wenn die Biotech-Fonds wirklich, wie Du schreibst, auf einer hohen Liquidität sitzen, wieso fällt dann der Fonds-Kurs??

Gruß
Dr.Hook

[Andalus]

Der Kurs der Fonds fällt, weil sie natürlich nie 100% Cash haben. Nur in diesem Falle wären sie unabhängig vom Biotech-Index. Dann wäre es aber auch kein Biotech-Fond!

[LudwigvanB]

@Dr.Hook,
Fonds können nicht einfach mal so Cash aufbauen. Der max. Cash-Anteil ist vorgeschrieben.
Wenn die Fonds-Anleger rausgehen, müssen die Fonds verkaufen, um Dir und mir das Geld überweisen zu können. Und was passiert, wenn verkauft wird? Die Aktien fallen.
Im der ersten Crash-Phase März - April 2000 fiel der DWS teilweise fast 15%/Tag !!! weil hunderttausende Anleger auf einmal verkauften. Und wie Du weißt, sind Fonds gezwungen, jede Deiner Verkaufsorders -und sei sie noch so groß- auszuführen.
LvB

[scarfaces]

MORGEN UND DIENSTAG WIRD ES KRÄFTIG RAPPPPPELN

FUTURES WIEDER MAL MINUS

[KMS]

@scarfaces

Irrtum: Nasdaq-Future + 0,9 %

MfG
KMS

[Immanuel_K]

... keine Kaufempfehlung, nur eine weitere Meinung von Yahoo finance. Habe ich wahrscheinlich nicht zum letzten Mal gepostet:

Friday March 16, 4:27 pm Eastern Time

Biotech stocks dragged down by rest of U.S. market

NEW YORK, March 16 (Reuters) - Biotech stocks slumped nearly 7 percent on Friday, dragged down with the rest of the beleaguered U.S. stock market despite what analysts insist remains a strong sector, sustained by reliable earnings growth.

``The biotech sell-off is part of the overall market slide, but the difference is biotechs are getting stronger and stronger,`` said analyst Caroline Pratt of Needham & Co.

``There seems to be a disconnect between stock prices going down and fundamental strength going up in biotechs. Investors are being pretty indiscriminate in what they are selling -- selling good companies with the bad.``
[...]
No stocks were safe from the sell-off.

``I don`t see any themes in the market today,`` said analyst James Reddoch of Banc America Securities. "It`s not like stocks trading at low multiples are safe. They are getting killed, as are stock with high multiples along with stocks that have no multiples.

``Apparently, investors are going to sell off all companies, quality or not, to the same levels of price-to-earnings to growth. Everything`s going to get beat up to the point,`` he said.

The large sell-off in biotechs, a sector that is off 26 percent from the start of the year and down 74 percent from its 52-week high back in September, has many industry analysts with strong ratings on some of the industry`s biggest names.

Earlier Friday, for example, Robertson Stephens analyst Michael King initiated coverage of Applied Biosystems as a buy and Celera Genomics Group as a long-term attractive.

Analyst Eric Schmidt of SG Cowen said that despite no bad news fundamentally in the sector, the majority of names are now trading at quite attractive levels.

``It`s tough in this market environment to stick a stake in the ground and say this is the end, but it feels like this is close to the bottom in biotech stocks,`` Schmidt said.

[woernie]

zwei argumente ziehen sich wie rote faeden durch alle diskussionen der letzten MONATE!! sowohl bei den techs als auch bei den bios. diese sind:
...it feels like it`s close to the bottom, bald muesste der boden gefunden sein oder so aehnlich. (seit nasdaq 3700 hoere ich den spruch!)

...fonds sitzen auf cash. ja wo denn? woher wisst ihr das denn? die mittelabflusse duerften zur zeit die zuflusse deutlich uebersteigen. die fonds sind vielleicht mal eine zeitlang auf cash gesessen. jetzt nicht mehr! gleev mi dat!

prinzip dieser beiden argumente:HOFFNUNG!

kann schon sein , dass wir einen rebound/technische reaktion/pullback (wohin?) sehen. kleine bearmarket-rallye eben. aber die jahreslows haben wir m.e. noch nicht gesehen.
strategie: entweder seitenlinie oder hit and run!

gruss woernie

[Immanuel_K]

Habe in einem anderen thread geschrieben, dass ich Bodenbildungs-Thesen gegenüber mittlerweile auch sehr skeptisch bin.

Fakt ist aber hinsichtlich der Biotechs, dass deren Fundamentaldaten in den meisten Fällen besser sind als vor einem Jahr (man vgl. diese Entwicklung mit Yahoo/Nortel/Compaq usw.).

[dosto]

Lass mal einen Blockbuster gegen Aids oder Krebs kommen,
dann knallt eine Bio Perle durch die Decke.

staatsanwalt schon mal darüber nachgedacht.

wenn ein blockbuster kommt, hat die eine firma gewonnen

und nun dostos frage
was machen wir mit den anderen companies, können die vorerst
ihre krebsforschung dann an den nagel hängen und die alte
forschung einfach abschreiben.

also wenn jetzt idec gewinnt
wo bleibt
pdli, mlnm etc. ich sage dir die kurse gehen in bach
und idec steigt ins unermessliche.

gruss dosto

[dosto]

Fonds können nicht einfach mal so Cash aufbauen. Der max. Cash-Anteil ist vorgeschrieben.
Wenn die Fonds-Anleger rausgehen,
ludwig
richtig trotzdem nicht ganz richtig.

kurzfristig kann ein funds sehr viel cash aufbauen,
ein janus bio-tech funds hat im märz letztes jahres
stolze 25% cash gehabt, und sie werden wohl zu den brüdern gehört haben (janus war total in) die den markt wieder angeschoben haben im mai-juni.

wenn aber verkaufdruck herscht, also im funds
was nützt dir dein cash,
du gibst cash ab an die anteileigner,
dieses würdest du aber zum anzetteln einer rally brauchen,
dein cash so sagt man -fadeaway- back to the investor.
auf gut deutsch es ist aus dem markt. nicht verfügbar.
das dumme bei funds ist, wenn einer raus geht, kommt er morgen nicht schon wieder, er ist erst mal ein halbes jahr wahrscheinlich weg. und wenn wir im april die statik erhalten und einige biot-techfunds so zwischen 17-30% in den miesen liegen, dann wird die halbe welt nicht sofort hurra schreien, jetzt kauf ich, sondern man denkt erst mal, jetzt hatts die auch erwischt (der keine unabhängige mann
geht da nicht rein)

gruss dosto

[dosto]

but the difference is biotechs are getting stronger and stronger,`` said analyst Caroline Pratt of Needham & Co.

das kannst du auch für einige ineternet-unternehmen und zulieferanten
anführen, viele machen wesentlich mehr umsatz als im
letzten jahr, also da kann das problem nicht liegen.

strong sind die auch.
bloß wie und wann verdient man geld

gilt für die
bio-techs genau so.

gruss dosto

[dosto]

apropo
bodenbildung


eine bodenbildung ist da wenn man sie sieht (im chart)
sie muss auch getestet werden, also 2mal da sein.

ein wunsch der bodenbildung, das darf jeder haben.
nützt aber keinem.

so zuviel dr posts
weißß nicht wie ich das alles in eine kriegen würde
sorry für die massenbelästigung.

dosto

[DerStaatsanwalt]

@ dosto Wenn ein Blockbuster kommen sollte gegen Aids oder Krebs, dann könnte das die initiale Zündung für das gesamt Segment sein. Wenn ein Hype ausbricht, dann ist er da, da wollen dann alle weider dabei sein und der Hype wird kommen

Wie du richtigt schreibts sitzen die Fonds auf riesigem Cash
Und genaus die werden dann einsteigen bei so einer Meldung
Die Kleinanleger etws später

[Immanuel_K]

... dann hätte ich mal eine grundsätzliche Frage zur TA (nicht nur, aber besonders an dosto):

Beispiel "Unterstützung": "eine Zone auf dem Chart unter den aktuellen Kursen, wo das Kaufinteresse stark genug ist, um den Verkaufsdruck zu übersteigen."
Murphy, Technische Analyse, S. 69.

Dazu die Frage: Im Hightech oder Biotechbereich ist die Wahrscheinlichkeit, dass Investoren ein Unternehmen heute noch genauso einschätzen wie vor 6 oder 12 Monaten viel geringer als im Fall von Unternehmen wie Ph. Morris oder Lufthansa. Projekte wurden aufgegeben, einem Medikament wird die Zulassung verweigert usw., mit entsprechenden akuten Folgen für die finanzielle Situation des Unternehmens. Kann da einer aus der Vergangenheit stammende Unterstützungslinie grosse Bedeutung zukommen?

Selbst im Fall der unfassenden Indices wie Nasdaq comp. wird der Wert charttechnischer Voraussagen durch stark veränderte ökonomische Rahmenbedingungen möglicherweise vermindert.

Andererseits kann aus der TA natürlich zur self-fulfilling prophecy werden, wenn die grosse Mehrheit der Marktakteure dran glaubt. Scheint mir aber eher (noch) nicht der Fall zu sein.

Grüsse, I_K.

[dosto]

Wie du richtigt schreibts sitzen die Fonds auf riesigem Cash


falsch
ich behaupte den funds läuft das geld davon (abflüsse)
fadaway- heißt dahinschmelzen oder so im deutschen.

also das cash das aufgebaut wurde wird abgezogen, zurückgegeben und kann daher auch nicht mehr in aktien gesetzt werden.
bei ungünstigen fall(kein cash flow - von hinten kommt auch nichts) darf der fondmanager wieder verkaufen um cash
aufzubauen.
das ist genau der falsche weg um kursgewinne zu erzielen.

falsch ist auch
ja ich will mal sagen ich pfeiffe auf deinen hype
es hat wohl ausgehypt.
meine meinung sagt klar
sollten blockbuster gegen hepathitis und krebs gefunden werden.
werden genau die leute (das muss ja nicht mal ne ag sein-
profitieren jetzt geht mal dostos fantasie durch (entweder
hat der kaerl gar keine und wenn dann so eine, werden jetzt viele sagen
also die
uni in bagdad meldet, wir haben ihn den allesauslösenden
krebsvirus, wir wissen was er tut, wir hauen ihm jetzt eine über die rübe. und wenn das stimmt mein freund, dann
gehen in amerika del norte bei den meisten bio-tech firmen
die aktien herausgegeben haben, schlichtweg die lichter aus.#

also wie schrieb schon ainer
the winner take it all
der rest
forget it.

gruss dosto

[dosto]

lieber königsberger

mein chartbild zeigt foldendes

der aufwärts-trend läuft bei mir auf der 450 er marke
die 500er marke sehe ich nicht als signifikant an.
spielt aber in dem falle keine rolle, weil sich trotzdem
durch zufall alles zwischen der 450-500 marke abspielen kann,
ich laufe halt etwas später ins dreieck.

zu den chartgurus, kann und will ich nichts sagen,
wenn einer das non plus ultra hätte, müßte er kein buch
schreiben, sondern würde vor lautewr aktienkaufe keine
zeit haben.
ich persönlich halte mich an die einfachste sache:
tends-trend-kanäle falls vorhanden,
also beim btk aufwärtstrend jetzt bei 450, muss halten,
wenn nicht etwas besserer widerstand bei 400, wenn nicht
klitze kleiner widerstand bei 350 und so weiter und so fort

aber meines erachtens gehts jetzt erst mal um den aufwärts-trend bei 450, der muss halten,
sonst ist eine 2 jährige rally des btk gebrochen-sprich obsulent,
nächst frage konsolidierung bei allen möglichen linien,

letzte frage
baisse
also absturz unter die 200 er linie.

thats what i see.
morgenstern, venus von milo, macd, slow, fast gestocher,
spielt mir alles keine große rolle.

ich will den weitblick
und zwar wertlos
teilnahmslos
unemotional
so als ob mich das eigentlich überhaupt nichts angeht.
charts werden rückwärtsgedacht sind sind daher meineserachtens
nur bedingt nach vorwärts zu benutzen
und zwar erst dann, wenn wieder bestimmte tatsachen vollzogen sind.

gruss dosto

[scarface7]

DIE BIOTECHS WERDEN DEMNÄCHST SCHÖN CRASHEN!!!!

ALLE VIE ZU HOCH BEWERTET!!!


STRONG SELL FÜR ALLE BIOTECHS!



AL PACINO

[gholzbauer]

[didiprotein]

@ Scarface

Aus deinen Kommentaren hört man echt reinen Neid und Mißgunst. Bist du sauer weil du den letzten Aufschwung verpasst hast? Ich aktzeptiere deine negative Meinung zu den Bios,nur nenne mir einmal ein paar Gründe die nicht nur oberflächlich sind und heißen Bios sind überbewertet!!! Sicherlich gibt es Werte die sehr hoch bewertet sind und diese Bewertung auch nicht halten können über kurz oder lang.Aber bedenke bitte,an der Börse wird Zukunft gehandelt. Hättest Du vor 15 Jahren an den Erfolg von Microsoft oder Intel geglaubt? Und genau diese Chancen haben PDL,MLNM,HGSI u.v.a.auch. Die Biotechnologie wird noch vieles in unserem Leben verändern! Und du wirst dir noch viele Tränen abwichen müssen,wegen den verpassten Kurschancen.

Gruß didiprotein
P.S. Ich würde mich sehr über eure Meinungen freuen.

[didiprotein]

Na,ihr beiden Superexperten! Hat es euch die Sprache verschlagen oder habt ihr keine Argumente mehr,die euer Geschwätze untermauern. Bios auch heute leicht im Plus!!!!!Nach dem Feiertag in Amerika am Donnerstag gehts bei den Bios richtig los. Dann gehts ab in Richtung 1100!!!!!!!!!! Wetten!

[scarface8]

MONTAG IST AVIRON DRAN!!!!


WERDEN BÖSE CRASHEN!!

-50%!!!
US panel not convinced spray flu vaccine safe
(UPDATE: adds company comment paragraphs 2,7-10, details paragraph 13, panel member comment paragraphs 16-17; edits throughout)

By Lisa Richwine

GAITHERSBURG, Md., July 27 (Reuters) - A U.S. advisory panel said on Friday it was not convinced that an experimental influenza vaccine sprayed into the nose was safe enough to win government approval.
ADVERTISEMENT



The decision by a Food and Drug Administration committee prompted maker Aviron (NasdaqNM:AVIR - news) to announce it could not bring the vaccine to the market in time for the upcoming flu season.

The product, called FluMist, could offer a pain-free alternative to annual flu shots. The FDA panel ruled that studies in 24,000 people showed the vaccine was effective in preventing the illness in kids as young as one year old and adults up to age 64.

But the panel voted 10-4 that information presented during a two-day meeting was insufficient to show FluMist was safe. Many members said further data might ease their concerns and they urged Aviron to continue development.

``I do think this vaccine will turn out to be safe but from the data we`ve seen ... I do think we need more information,`` said Judith Goldberg, director of biostatistics at New York University School of Medicine.

FluMist is key to the future of Aviron, which is trying to get its first product on the market. Industry analysts predict FluMist, which American Home Products Corp. (NYSE:AHP - news) would co-market, could generate $1 billion in annual sales in a few years if it gets FDA clearance.

Aviron Chairman and Chief Executive Boyd Clarke told reporters after the panel vote that, ``we will not be able to launch this vaccine in time to participate in the 2001-2002 flu season.``

The company had hoped to have limited quantities available for the upcoming flu season, which usually begins in the fall and peaks in the winter.

``Our primary objective still remains securing licensure of this vaccine in order to participate in a full launch for FluMist in 2002,`` Clarke said.

Aviron is continuing to provide data on FluMist`s safety to the FDA, he added.

About 70 million people get flu shots each year to prevent the fever, aches and misery the illness brings. Flu complications kill 20,000 Americans each year and send 100,000 people to the hospital.

FluMist contains live, weakened flu strains that are sprayed up the nose to stimulate immunity against the virus at a place where it enters the body. Flu shots are made with killed flu viruses.

Panel members said they were concerned about a lack of information on how FluMist affected people with asthma or weak immune systems, as well as children who were given other immunizations at the same time.

Aviron said FluMist`s most common side effects were mild, such as a runny nose.

In one clinical trial, FluMist provided children with 95 percent protection from feverish illnesses and 97 percent protection from ear infections, a common flu complication.

Panelists said FluMist`s easy administration made it appealing for use in children, a group hard-hit by the flu, but not commonly vaccinated with shots.

``As a pediatrician, I am really very excited about the possibility of having an effective, relatively safe vaccine with ease of administration,`` Dr. Walter Faggett said.

Studies in adults were less successful, failing to show that FluMist reduced feverish illness during a flu outbreak compared with a placebo spray. Data did show FluMist cut rates of severe illness and upper respiratory infections.

Company studies did not compare FluMist to a flu shot.

Trading of Aviron shares was halted during the panel meeting. Aviron is based in Mountain View, California.

[scarface8]

MORGEN BIOTECH CRASHHHHHHHHHHHHHHHHHH!!!!!!

BESONDERS STEM!!!!!

[scarface8]

July 31, 2001

House Votes to Ban All Human Cloning
By THE ASSOCIATED PRESS


Tangled Issues in Congress: Cloning and Stem Cell Study (July 31, 2001)

200 in Congress Endorse Stem Cell Research (July 28, 2001)

Stem Cells Hint at Promise for Inborn Brain Diseases (July 27, 2001)

Grappling With the Ethics of Stem Cell Research (July 24, 2001)



ASHINGTON -- The House voted to ban all cloning of human embryos Tuesday night, casting Congress` first votes on the divisive ethical issue after a day of emotional debate on science, morality and the definition of life.

The bill passed by 265-162, capping a day in which lawmakers also said no to even limited human cloning for research into possible cures for Alzheimer`s, Lou Gehrig`s and other fatal or disabling diseases.

"This House should not be giving the green light to mad scientists to tinker with the gift of life," said Rep. J.C. Watts, R-Okla. "Cloning is an insult to humanity. It is science gone crazy."

A similar ban has been introduced in the Senate by Sen. Sam Brownback, R-Kan. And Senate Majority Leader Tom Daschle of South Dakota said Tuesday he was "opposed to the effort to clone under virtually any circumstances."

The vote to ban any human cloning occurred shortly after the House, by 249-178, rejected an amendment that would have allowed the limited creation of cloned embryos dedicated solely to research.

Reps. Jim Greenwood, R-Pa., and Peter Deutsch, D-Fla., said their alternative to permit cloning for research could point the way to cures for terrible diseases.

"Why would we condemn the world and future generations not to have this miracle?" Greenwood said. "Some would say once you put Mr. Greenwood`s cheek cell in and it divides, it becomes a soul."

Lawmakers spent much of the day`s debate plunging into the ethics of biotechnology.

"This is about providing moral leadership for a watching world," said Rep. F. James Sensenbrenner, R-Wis., the chairman of the Judiciary Committee. "Allowing the creation of cloned embryos by law would enable anyone to attempt to clone a human being."

House members agreed on the general principle that they do not want the human species cloned, the technique that allowed scientists to create Dolly the sheep in 1997.

The disagreement was over whether scientists should be able to clone human embryos and then use them in their search for cures to diseases.

From the embryos, scientists could gather valuable stem cells -- the building blocks for all human tissue. President Bush is now deciding whether to permit federal funds for medical research on stem cells pulled from human embryos.

The matter has been hotly contested because the most versatile stem cells are derived from embryos discarded at fertility clinics. Using them for research is opposed by abortion foes.

"There are ways for us to get these answers without messing with cloning," Rep. Billy Tauzin, R-La., supporting the total ban written by Reps. Dave Weldon, R-Fla., and Bart Stupak, D-Mich.

Cloned embryos would represent a new frontier, allowing scientists to produce stem cells that would be a perfect match to a person`s DNA. Such stem cells could then be cultivated to produce healthy tissue for people with debilitating diseases, scientists hope

But even a cloned embryo is a human being, opponents argued, saying Greenwood`s bill would sanction their destruction.

"You might as well say Dolly isn`t a real sheep even though she`s now five years old," said Rep. Joseph Pitts, R-Pa.

Sensenbrenner and others suggested that scientists could use adult stem cells or other sources for research.

The Food and Drug Administration claims the authority to regulate cloning, but there is no law governing it.

"We are sailing into uncharted waters," Rep. Louise Slaughter, D-N.Y., said. "Our decision here today could have consequences for years to come."

In a statement Monday, the Bush administration said it "unequivocally is opposed to the cloning of human beings either for reproduction or for research. The moral and ethical issues posed by human cloning are profound and cannot be ignored in the quest for scientific discovery."

The use of stem cells from human embryos for research has divided even the most staunch anti-abortion Republicans. In recent weeks, some, such as Sen. Orrin Hatch of Utah, have announced their support for stem cell research.

Recently during Bush`s trip to Europe, Pope John Paul II urged him to reject research with human embryo stem cells.







WOWWWWWWWWWWWWWWW


CRASHHHHHHHHHHHHH

[HSM]

AL PACINO JAGT BIO

ALFRED BIOLEK

JA LECK

.

[HSM]

[scarface8]

MEEN KUMPELLLL






MORGEN BIOTECH CRASHHHHHHHHHHHHHHHHH


BIOLEK FIND ICH GUT

[HSM]

JA BIOLECKS

.

[blauerDiamant]

Zitat aus einem anderen Thread:

von thehunter

bios--> strongest no scientific use or cloning of stemmcells sell!!!!!!!!!!!!!

[didiprotein]

@ scarface
Wetten daß der Nasdaq Biotech Index am Ende des Jahres bei über 1100 Punkten liegt!!!!!!!!!!!!!!!!

[scarface8]

Protein Design reports lower Q2 profits
FREMONT, Calif., Aug 2 (Reuters) - Biotechnology company Protein Design Labs Inc. (NasdaqNM:PDLI - news) on Thursday reported lower second-quarter earnings as higher spending outpaced a 6 percent increase in revenues.

Protein Design, which specializes in developing antibodies to treat diseases, said it had net income of $3.1 million, or 7 cents per diluted share, compared with net income of $5 million, or 12 cents per share, a year ago.

Estimates from Wall Street analysts ranged from a profit of 1 cent per share to 10 cents per share, with an average of 6 cents per share, according to Thomson Financial/First Call.

Second-quarter revenues rose to $21.6 million from $20.4 million in the same 2000 quarter. Total costs and expenses in the second quarter were $18.5 million, compared with $15.3 million a year earlier.

Looking ahead, the company repeated previous guidance that it expects to post near break-even results by the end of 2001, despite costs and expenses rising by between 20 percent to 25 percent.

[scarface8]

Noven Pharmaceuticals warns of lower 2001 profits
MIAMI, Aug 2 (Reuters) - Noven Pharmaceuticals Inc. (NasdaqNM:NOVN - news), a maker of drug delivery products, announced on Thursday slightly lower second-quarter profits and warned that its full-year results would fall short of expectations due to a lack of product orders.

Noven reported net income of $3.2 million, or 14 cents a diluted share, for the second quarter of 2001, compared with $3.5 million, or 15 cents a share, in the year-earlier quarter. The company said its income before taxes for the quarter was a record $4.7 million, while revenues rose to $12.6 million from $10.5 million for the same quarter in 2000.

Wall Street analysts on average had expected Noven to earn 14 cents a share in the latest quarter.

Noven said the second half of the year would present a challenge because it had not received certain expected product orders from Novartis Pharma AG that are important to the continued growth of its international business.

Noven said it now expects revenues for 2001 to be modestly higher than the $42.9 million reported last year. Pre-tax income should increase 25-35 percent over the $12.0 million reported for 2000, it said, which at assumed tax rates would yield net earnings per share of 40-45 cents. The current First Call estimate for the company`s 2001 EPS is 66 cents.

[scarface8]

NR.3!!! WARNUNG

ALLE BIOTECHS STRONG SELL!!!!!!!!!!


Genencor 2nd-qtr profit, full year estimate, drop
NEW YORK, Aug 2 (Reuters) - Biotechnology company Genencor International Inc.(NasdaqNM:GCOR - news) said on Thursday its second-quarter earnings fell 20.6 percent, and warned that earnings for the year will be lower than expected.
ADVERTISEMENT



The Palo Alto-based company, which focuses on enzymes that catalyze chemical reactions in the health care, agriculture and industrial chemicals markets, said net profit fell to $2.3 million, or 4 cents a diluted share, from $2.9 million, or 5 cents a share, in the year-ago quarter. The results included a one-time net gain of $900,000 from the sale of securities.

``We are continuing to significantly increase our investment in research and development,`` said Raymond Land, Genencor`s chief financial officer, in a statement.

The results exceeded the average analyst estimate of 3 cents a share, according to a poll by Thomson Financial/First Call. Revenue rose 2 percent to $81.35 million from $79.69 million in the year-ago quarter.

Still, the company said it expects fully diluted earnings per share for 2001 of 15 cents a share, 7 cents lower than the average analyst estimate of 22 cents.

The lower earnings reflect a lower product revenue target of about $310 million for the full year, the company said.

``We are investing in our health care initiative at a 12-month run rate of $25 million, which is funding 10 development programs, a significant increase in staff, and several new collaborations,`` Land said.

[scarface8]

But Noven Pharmaceuticals Inc. (NasdaqNM:NOVN - news), a maker of drug delivery products, tumbled to $23.57 in after-hours trading from its finish of $33.32 on the Nasdaq. The company posted slightly lower quarterly profits and warned full-year results would fall short of expectations due to a lack of product orders.

Biotechnology company Protein Design Labs Inc. (NasdaqNM:PDLI - news) fell to $48.51 in extended hours from its close of $54.41 on the Nasdaq. Protein Design Labs reported lower quarterly earnings amid higher spending and said it still expects nearly break-even results for full-year 2001.

[scarface8]

Lehman Cuts Outlook for Protein Design
NEW YORK (Reuters) - Lehman Bros. on Friday cut its earnings outlook for biotechnology company Protein Design Labs Inc. (NasdaqNM:PDLI - news) for both 2001 and 2002.

Lehman cut its estimate for 2001 earnings per share from 11 cents to 5 cents, and cut 2002 from 14 cents to 13 cents.

``Given that fees and milestone payments ... are difficult to predict, we are taking operating revenues this year down from $48.0 million to $43.9 million,`` analyst M. Wood wrote in a research report.

Shares of Protein Design closed at $54.41 on Thursday on the Nasdaq before the company reported lower second-quarter earnings.

[kragen]

@scarvace

hast in deinen i-nets sicherlich viel geld verloren.
jetzt wünscht du dir ,das den bios das selbe wiederfährt.
was du von dir gibst könntr man meinen das du deinenbenutzernamen geändert hast.

war der vielleicht mal trademaster

hört nicht auf trademasters gesabber wir haben ja verfolgen können was mit seinen werten passiert ist

kragen

[scarface8]

DIE BIOTECHS GEBEN WIEDER SCHÖN NACH



STRONG SELL!!

[kragen]

hallo trademaster wie gehts dir.
bestimmt hast du riesengewinne eingefahren mit ariba,c1 usw.
die verluste der bios halten sich noch in grenzen.


kragen

[scarface8]

WATTT?? WER BIST DU DEN??? KRAGEN???
WAS HABT IHR BLOß MIT DEM TRADEMASTER????
WER IST DAS?
EGAL
VIEL SPAß MIT DEN BIOTECH VERLUSTEN

[didiprotein]

@scarface8
Viel Spaß mit deinen B2B Verlusten!HA!HA!HA!

[scarface8]

WATTT?WER IST TRADEMASTER????
PANNE ODER WATT????

IHR ARMEN BIOTECH ANLEGER

[didiprotein]

@scarface
Im Gegensatz zu Dir du B2B Spezialist (du bist schon arm)haben die biotechanleger noch Hoffnung,oder einige wie ich z.B. sind vor 2 Jahren in die großen Werte von Heute hinein.Somit bin ich immer noch gut im Plus und habe noch Geld genug um günstig nachzukaufen.Der einzige Arme bist du.B2B Werte haben keine Fantasie mehr!

[scarface10]

TJA

BIOTECHS FALLEN SCHÖN


ALLE BIOTECHS ZU HOCH BEWERTET!


STRONG SELL!

[SCARFACE13]

BIOTECHS FALLEN SCHÖN

UND DAS IST GEIL


ABGX WIRD NACHBÖRSLICH KALT GEMACHT
GEIL
Thursday January 3, 5:27 pm Eastern Time
Abgenix slumps after ending drug trials
NEW YORK, Jan 3 (Reuters) - Shares of drugmaker Abgenix Inc. (NasdaqNM:ABGX - news) slumped in extended hours trading on Thursday after it said it will not explore use of its antibody-based drug ABX-IL8 as a treatment for rheumatoid arthritis.

The company said the drug did not prove effective in a mid-stage clinical trial.

Abgenix fell to $25.18 on the Instinet electronic brokerage system from Thursday`s close of $31.68.







nachbörslich -20%!!!!!


IMCLONE FÄLLT AUCH.....FÄLLT UND FÄLLT...


GEIL

[gholzbauer]

Was bist du denn für ein armes Würstchen, scarface?
Bist du dir so sicher, selber nie Arthritis zu bekommen???
Ich will dir mal zugute halten, daß du etwas doof bist und nicht weißt, was du von dir gibst.

[didiprotein]

@scarface
Ich weiß nicht an welcher Krankheit du leidest,aber es muß schon ziemlich ernst sein!!!
didiprotein
P.S.
NBI bisENDE 2002 bei 1600 Punkte!!!

BTK bis ENDE2002 bei 900 Punkte!!!

[@Alle]

gholzbauer,didi
was ist euer problem?


ich freu mich auch ,das die bios abschmieren!

das wird noch andauern!

alles noch zu teuer!

[gholzbauer]

Zu denken, Biotechs seien zu teuer, ist eine Sache.
Sich jedoch über fehlgeschlagene Medikamentenentwicklung zu belustigen wie scarface, zeugt von einer fragwürdigen Geisteshaltung, vorsichtig ausgedrückt.

[drpaulo2001]

Hallo jungs ,scarface hat recht.Bio knallen weiter nach unten.Grund:jetzt ist die ernte vom Weihnachtsgeschäft,alles knallt nach oben außer die bios.Wenn die Bereinigung wieder kommt ,da bin ich sicher so ab ende Januar ,dann gehen die bios noch weiter nach unten. Ziel bis Oktober so 700 punkte ,Dow 12000 ,Dax 5200,Nasdaq 1700.Glaubt es geht weiter nach unten .Oder denkt ihr es ist wie 1997,wo alles bekann .Also ich denke die nächsten 3 Jahre ist absolutes stock picking angesagt .drpaulo

[drpaulo2001]

Sorry ,ich wollte noch sagen das meine Favoriten nabi und vertex sind.

[@Alle]

tja jungs.....


die bios fallen weiter!!!!!


und sie werden NOCH weiter fallen!!!!

alles noch zu teuer



OHNE WORTE!!!



imcl erst bei 25$ ein kauf

mlnm erst bei 15$ ein kauf

medx erst bei 10-12$ ein kauf!



Bye!!!!

[Kelbi]

@scarface8

Intel hat heute nen neuen Microprozessor mit 2,2 Gigaherz rausgebracht. Wenn Du mir beschreibst wie der funktioniert. glaub ich dir auch, das Du Biotechempfehlungen aussprechen kannst............

[Kelbi]

Leute lasst euch Doch nicht von den verflossenen B2B Fans verrückt machen, die kommen auch noch zu ihrem Recht.

Aber der Grundsatzrend bei Bio und Pharma ist nunmal das der Durchschnitt immer älter wird etc.........

Beispiele 2001 PRX, IART,BNT dagegen ist Ariba(zumindest 20001...........)


nichts für ungut

Kelbi

[DerHabicht]

@ @Alle
Das Argument, daß die irgendeine Branche zu teuer ist, haben die Institutionellen schon immmer
gut für Schaffen von Volalität für ihre Trades eingesetzt.
Die Bios fahren einfach einen Schlingerkurs. Wer aber für längere Zeit investiert, ist dies
nicht so sehr von Bedeutung.



Ich sehe vielleicht 10-15 % durchschnittliche Abschwächung.

Gruß

[FockeWulf190D]

@ Alle ,Endlich mal einer, der es begriffen hat.

DIE BIOS FALLEN WEITER STRONG SELL !!!!

[@Alle]

OHNE WORTE!

IMCL -14%
31$

MEDX -3%
16$

Biotechs weiterhin STRONG SELL!!!

[FockeWulf190D]

STROOOOOONG SELL !!!

[CHAPTER7]

bios strong sell!!!!!!!!!!!!

[@Alle]

bios weiterhin Strong Sell!!!!!!!!!!!!

[@Alle]

bios weiterhin Strong Sell!!!!!!!!!!!!

[FockeWulf190De]

STROOOOOOOOOOOOOOONG SELL

[gholzbauer]

Iss ja gut. Daß du alles verloren hast, tut und leid, kannst ja ein Rückforderungsgesuch bei den derzeit machthabenden Sozialisten einreichen ... viel Spaß ...

[@Alle]

STRONG SELL!
für bios!!!





werde ich zu 15$ kaufen!!!!!




werde ich zu 12$ kaufen!!!

[@Alle]

Tuesday January 22, 6:21 pm Eastern Time
UPDATE-1 Millennium 4th-qtr loss widens on higher R&D
(UPDATE: Adds details)

NEW YORK, Jan 22 (Reuters) - Millennium Pharmaceuticals Inc. (NasdaqNM:MLNM - news) said on Tuesday its fourth-quarter loss widened as revenue from partnerships fell and spending on new drug development soared.
ADVERTISEMENT



The Cambridge, Massachusetts-based biotechnology company said its net loss widened by 79 percent to $66.97 million, or 30 cents a share, from $37.49 million, or 18 cents, in the year-ago quarter.

Revenue fell 7 percent, to $54.6 to from $58.7 million on declining milestone payments from pharmaceuticals companies with which Millennium is developing drugs.

Millennium, which began life as a gene-hunting company, now has aspirations to be a pharmaceuticals company. It is working to develop inflammatory, metabolic, and cancer drugs, but has yet to bring a product to market.

Excluding amortization charges, debt conversion expenses, the cost of an accounting change, and deemed preferred stock dividend, the company posted a loss of $50.4 million, or 23 cents a share, from a loss of $15.6 million, or 7 cents, a year earlier.

Analysts had expected the company to post a loss before items of between 12 cents and 26 cents a share with an average estimate of 19 cents, according to Thomson Financial/First Call.

Making new drugs from new genetic information is taking longer than some experts had expected. To generate revenue in the shorter term, Millennium is moving outside its traditional areas of expertise.

In December, it agreed to acquire Cor Therapeutics Inc. (NasdaqNM:CORR - news) for $2 billion in a bid to enter the lucrative market for heart drugs. Cor`s sole product is Integrilin, a drug used in hospitals to prevent blood clots.

Millennium reiterated its projection that it expects to record about $150 million in Integrilin sales in 2002, and total revenue of more than $400 million.






strong sell!!!!!!!!!!!!!!!!!!!!

alle bios

[@Alle]

Sepracor`s Q4 loss wider than expected (SEPR) By Julie Rannazzisi
Sepracor (SEPR) reported a fourth-quarter net loss of $102.3 million, or $1.31 a share, vs. $73.4 million, or $1.00 a share, for the fourth quarter of 2000. The loss was wider than the $1.24 that had been expected by Thomson Financial/First Call. Fourth-quarter revenue totaled $37.3 million, with revenues from pharmaceutical product sales approximately $32.2 million. That compared to revenue of $24.4 million in the same period in 2000. The Marlborough, Massachusetts.-based pharma company saw its shares close up 4.8 percent to $52.31 on Tuesday.

[FockeWulf190De]

STRONG SELL !!

[SCARFACE13]

OUCH!!!!!!!9:01am 02/21/02 Myriad drops on Pru`s `sell` rating (MYGN) By Tomi Kilgore
Shares of Myriad Genetics (MYGN) are sliding $3.99, or 10 percent, to $35 in pre-open trading, after Prudential Securities initiated coverage of the biotech company with "sell" rating and $25 price target. Analyst Christopher Raymond said he sees "significant" commercial, collaborative and clinical risk in the coming quarters. For commercial risks, he does not believe the company`s genetic tests add much to the treatment decision, and therefore may not be the high growth products investors are anticipating. He also noted that Myriad has not "monetized" much of the committed capital from its development partners, "possibly due to an inability to reach certain milestones." Finally, he feels investors have "significantly underestimated" the study size and duration required in Phase I/II testing of Flurizan -- a treatment for early stage prostate cancer -- required to show a therapeutic effect. Raymond also started coverage of a number of other biotech firms, but none with a rating below "hold."



AGGRESSVISE SELL MYGN!!!!!!!

[SCARFACE13]

OUCH!!!!8:40AM Human Genome cut by TWP; mirostipen won`t be blockbuster (HGSI) 23.53: Thomas Weisel Partners downgrades to MKT PERFORM from Buy based on view that one of co`s lead drugs (mirostipen) has a low chance of becoming a significant revenue generator. Believes concerns about the drug will remain over HGSI`s share price in the near term.





AGGRESSIVE SELL ALL BIOTECHS!!!!!!!!!!!




AL PACINO

[SCARFACE13]

US-Biotechs - Nix wie raus!

Wir müssen draußen bleiben! So oder so ähnlich müssen die Anleger von Biotechnologiefirmen angesichts der Kursrallye an Wall Street gedacht haben, bei der sie am Montag zwar zuschauen, nicht aber teilnehmen durften.

Während sich der Nasdaq Composite im Tagesverlauf zu einem beeindruckenden Plus von 2,6 Prozent aufschwang und auch der in 2002 bis dato schlechteste Performer unter den Indizes, der Amex Internet Index, einen Satz um 3,7 Prozent machte, gelang dem Amex Biotech Index mit Mühe und Not der Sprung über die Nulllinie.

Das Stimmungsbarometer für die Biotechnologiebranche beendete den Handel bei 487,52 Zählern, ein Anstieg gegenüber Freitag von gerade einmal 0,2 Punkten bzw. 0,04 Prozent. Das Pendant an der NASDAQ, der Nasdaq Biotech Index, schloss sogar 0,8 Prozent leichter bei 750,21 Zählern.

Ausschlaggebend für die enttäuschende Entwicklung waren Verluste unter anderem bei Human Genome Sciences [Nasdaq: HGSI Kurs/Chart ]. Die Aktien verloren nach einer Abstufung von Thomas Weisel Partners auf "Market Perform" (von "Buy") 1,63 Dollar bzw. 7 Prozent auf 21,90 Dollar. TWP-Analyst Paul Knight schrieb in einer Notiz an seine Kunden, dass das experimentelle Medikament Mirostipen nur wenig Chancen auf eine Marktzulassung habe und selbst für den Fall einer solchen kaum zum Megaseller würde.

Auch bei Isis Pharma [Nasdaq: ISIS Kurs/Chart ] kam es zu kräftigen Kursverlusten, nachdem das Unternehmen gesagt hatte, die Wirkung eines experimentellen Medikamentes gegen Schuppenflechte habe nicht die Erwartungen erfüllt. Die Titel verloren daraufhin 2,55 Dollar bzw. 14 Prozent auf 15,40 Dollar.


Keinen Deut besser fielen die Nachrichten beim Nischenplayer Agniotech [Nasdaq: ANPI Kurs/Chart ] aus. Die kanadischen Forscher räumten am Montag ein, dass ihr experimentelles Medikament zur Behandlung von Multipler Sklerose bei den Patienten nicht die gewünschte Wirkung gezeigt habe. Die Anleger zögerten keine Sekunde und knüppelten die Aktien um 10,66 Dollar bzw. 20 Prozent auf 43,23 Dollar.

Die Titel von ImClone [Nasdaq: IMCL Kurs/Chart ] konnten von der Kursrallye ebenfalls nicht profitieren und fielen um 0,97 Dollar bzw. 6 Prozent auf 14,73 Dollar. Die Firma wird sich voraussichtlich am heutigen Dienstag mit Vertretern der Food & Drug Administration (FDA) treffen, um über das Anti-Krebs-Medikament Erbitux zu beraten. Die Behörde hatte Ende letzten Jahres ihre Genehmigung zur Markteinführung von Erbitux wegen ungenauer Forschungsdaten verweigert.





BIOTECHS AGGRESSIVE SELL!!!!!!!!!!!!


AL PACINO

[@Alle]

Thursday March 7, 11:00 am Eastern Time
Sepracor Shares Tank on News FDA Plans to Reject Company`s Allergy Drug

MARLBOROUGH, Mass. -- Sepracor Inc. (NasdaqNM: SEPR - news) said the Food and Drug Administration plans to reject its new drug application for allergy-relief medication Soltara because of safety concerns.

The news pushed shares of Sepracor (SEPR) down $27.94, or 59%, to $19.33 in midmorning trading Thursday on the Nasdaq Stock Market.

The specialty drug maker said the FDA notified the company Wednesday that it intends to issue a "not approvable" letter for its Soltara brand tecastemizole 15-milligram and 30-milligram capsules. A "not approval" letter is issued if the FDA believes that the application contains insufficient information for an approval action....



-60%!!!!!!

[@Alle]

Thursday March 7, 11:14 am Eastern Time
Celgene says Thalomid cancer application delayed
(UPDATE: Adds details, stock price, analyst comments paragraphs 1-3, 6-8, 10, 12, previous WARREN, N.J.)

By Jed Seltzer

NEW YORK, March 7 (Reuters) - Drug developer Celgene Corp. (NasdaqNM:CELG - news) on Thursday said an application to market its Thalomid drug for use in cancer patients would be delayed by at least two years because the company must conduct an additional clinical trial, sending its stock tumbling.
ADVERTISEMENT



Celgene said that after discussions with the U.S. Food and Drug Administration the trial would be required before the company could seek marketing approval to treat patients recently diagnosed with a cancer known as multiple myeloma.

Shares of Celgene slumped 17 percent, or $4.72, to $23.05 in Thursday morning trading, placing the stock among the largest percentage losers on Nasdaq.

Although Thalomid is currently approved only to treat leprosy, the bulk of its sales are generated from cancer-related uses -- a phenomenon known as ``off-label`` prescribing, which doctors are permitted to do. Thalomid is Celgene`s top-selling product.

The company said existing data from mid-stage clinical trials in cancer patients would not be submitted to the FDA until the additional trial is completed. Warren, New Jersey-based Celgene said the process would take about 24 months but would not affect 2002 financial results.

But analyst Jason Zhang of Stephens Inc. said the delay to marketing approval could hurt 2003 and 2004 revenues, as Celgene would still be unable to actively promote the off-label use to cancer doctors.

``The FDA is really tightening up the regulatory process and raising the bar for approval,`` Zhang said. ``Certainly the timeline for Thalomid has been changed, but the bright side is the drug is already on the market. What the approval would allow them to do is to go talk to oncologists.``

The FDA suggested that a large late-stage, or Phase III, trial would strengthen Celgene`s bid to treat multiple myeloma with Thalomid, a Celgene spokeswoman said. The company had previously hoped to support a marketing application by relying on its Phase II trial data as well as evidence from cancer patients treated off-label.

Analysts and investors had hoped Celgene would be able to submit an application seeking marketing approval for multiple myeloma as early as this year.

Patients with multiple myeloma have defective ``plasma cells`` that are developed from white blood cells. The plasma cells multiply and create tumors in the bone marrow, as well as produce a large quantity of abnormal antibodies in the blood or urine.

Thalomid`s main chemical, thalidomide, was associated with significant birth defects after it was taken by pregnant women decades ago as a treatment for morning sickness.

But the company spokeswoman said safety was not an issue in discussions with the FDA over an additional trial.

The company on Jan. 30 projected that 2002 Thalomid sales would reach $100 million to $120 million. Celgene`s total product sales for 2001 were $84.2 million.

Celgene Chairman and Chief Executive John Jackson said in January that ``upside`` to the 2002 Thalomid sales target would depend on the presentation and publication of data from clinical trials of Thalomid in solid tumors. If oncologists see supporting data on the efficacy of a cancer product, they are often more likely to administer it to patients.

However, analysts have said they were disappointed the company did not provide an exact timeline for the presentation of cancer data or the submission of a marketing application to the FDA.

In addition to Thalomid, Celgene and Novartis AG plan to co-market Focalin, a refined version of the legendary drug Ritalin, as well a tweaked version of the drug called Ritalin LA.




-20%!!!!

[@Alle]

Raus AUS BIOTECHS!!!!!!!!!


Biogen tumbles on rival FDA win
Sun Micro higher on outlook, broker sour on CIEN, JDSU

By Emily Church, CBS.MarketWatch.com
Last Update: 6:48 AM ET March 8, 2002




LONDON (CBS.MW) - Biogen shares tumbled 12 percent in pre-open trading on Friday after its Swiss rival Serono SA announced it has received FDA approval to market its multiple sclerosis drug Rebif in the U.S.

Biogen (BGEN: news, chart, profile) was trading around $49.50, dealers at Madoff Securities in London said. That is down from a $56.40 New York close on Thursday. The decision means Serono (SRA: news, chart, profile) can market, or sell, the drug in the U.S. and compete vs. Biogen`s Avonex.

"We`ll be ready to go in a few days" in the U.S. market, a Serono spokesman said. The company has sales of $380 million in 2001 outside of the U.S. with the drug for a 38 percent market share outside the U.S.. It`s targeting a 25 percent share of U.S. market over the next three to four years, the spokesman said.

Serono learned of the FDA approval overnight, he said. Serono shares spiked 12 percent in Europe. Other competitors include Betaseron produced by Germany`s Schering AG (SHR: news, chart, profile), where shares were down 4 percent in Frankfurt, and Copaxone, produced by Israel`s Teva (TEVA: news, chart, profile).

[puhvogel]

Guten Morgen

Serono learned of the FDA approval overnight, he said. Serono shares spiked 12 percent in Europe.

[@Alle]

Der gestrige HORROR!!!!!Corixa Shares Fall After FDA Delays Approval of Cancer-Fighting `Smart Bomb`
SAN FRANCISCO (AP) -- Shares of Corixa Corp. (NasdaqNM:CRXA - news) fell sharply Wednesday after the U.S. Food and Drug Administration demanded that the company conduct additional human tests on its experimental cancer drug Bexxar before the agency would consider approving it.
ADVERTISEMENT



Bexxar is part of a promising new class of drugs dubbed "smart bombs" for their ability to target cancer cells with their radioactive payloads while leaving healthy cells alone. The FDA said the Seattle-based biotechnology company needs more proof that Bexxar is safe and effective in treating non-Hodgkins lymphoma.

"We are extremely disappointed," Corixa chief executive Steven Gillis said in a statement.

Corixa said it will request a meeting with FDA officials "for further discussion of a regulatory path for Bexxar."

Corixa is co-developing the drug with GlaxoSmithKline. Corixa`s closing share price on the Nasdaq Stock Market was down $3.48, or 36 percent, to $6.15 on Wednesday, while Glaxo`s share price was up 14 cents to $48.81 on the New York Stock Exchange.

Corixa took control of Bexxar in 2000 when it purchased the drug`s original developer, South San Francisco-based Coulter Phamaceuticals Inc., for stock valued at $900 million when the deal was announced.

"I think it`s fair to say that Corixa isn`t getting the return it had hoped from the acquisition," said Brian Rye, an analyst with Raymond James & Associates Inc. Rye said it may take up to two more years for the drug`s approval if the FDA requires Corixa to conduct another clinical trial from scratch.

But Corixa`s bad news was good news for competitor Idec Pharmaceuticals of San Diego, which last month received FDA approval for a similar drug for the same disease, Zevalin. Idec`s stock was up $2.93 a share, or 4 percent, to $69.31 in trading on the Nasdaq Stock Market.

------

On the Net:

Corixa: http://www.corixa.com

FDA: http://www.fda.gov

Idec: http://www.idecpharm.com




Der heutige HORROR!!!!!!

8:43AM ViroPharma initiated with Sell rating at Fulcrum (VPHM) 17.50: Fulcrum initiates VPHM with a SELL rating; firm believes that the March 19 Antiviral Drugs Advisory Committee meeting for Picovir will result in a recommendation against approval to the FDA, which could prompt a selloff of the shares down to as low as $7.50; firm is also concerned about what it views as a very weak co-promotion partnership as well as a director`s recent stock sales and hedging arrangement.


STRONG SELL!!!!!!!!!!!!!




Raus aus Biotechs!!!!!

[SCARFACE13]

Tuesday March 19, 2:51 pm Eastern Time
US FDA advisers turn down ViroPharma common cold drug
(UPDATE: Adds background on Picovir)

GAITHERSBURG, Md., March 19 (Reuters) - A U.S. advisory panel on Tuesday rejected ViroPharma Inc.`s (NasdaqNM:VPHM - news) common cold treatment Picovir, the first drug to attack the cause of the illness and not just the symptoms.

The panel voted unanimously to urge the Food and Drug Administration (FDA) to decline to approve Picovir. The agency usually follows its panels` advice.

Aventis SA (NYSE:AVE - news) is co-developing Picovir, known generically as pleconaril.

The drug strikes viruses that cause more than half of all colds, and ViroPharma`s studies showed it cut the illness short by about one day.

Patients need to start taking Picovir within 24 hours after symptoms start. Treatment lasts five days, and the drug must be taken with food three times a day. Approval by the FDA would make Picovir available by prescription only.

Picovir works by sliding into a pocket on the surface of picornaviruses. By occupying the pocket, Picovir prevents the virus from copying itself and infecting healthy cells.

[SCARFACE13]

Hemosol Announces that Hemolink Will Not be Cleared for Marketing in Canada This Year
TORONTO, March 20 /PRNewswire-FirstCall/ - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today announced that it has been advised by Health Canada that the Company`s Canadian New Drug Submission (NDS) for Hemolink(TM) (hemoglobin raffimer) will not be approved at this time. Additional data will be required in a re-filed NDS. The Company expects to receive details of Health Canada`s requirements in a pending Notice of Non-compliance/Withdrawal letter.

``We took the initiative to file in Canada first and this has provided us with valuable guidance that will allow us to further the commercialization of HEMOLINK,`` said John W. Kennedy, President and Chief Executive Officer of Hemosol. ``We will evaluate the details of the response from Health Canada when we receive it, and after full consideration, make the appropriate decisions with respect to the priority of a re-filing in Canada relative to opportunities for HEMOLINK in other countries.``

Hemosol remains in active pursuit of approval to market HEMOLINK in the United Kingdom, Europe and the United States. The Company`s recently launched clinical trials, designed to meet U.K. and U.S. regulatory approval requirements, remain on schedule to be completed in the second quarter of 2002, with results to be available and reported in the third quarter of 2002. Results from these trials will be used to strengthen the Company`s pending application in the U.K.

Work on the Company`s new facility is proceeding on schedule. Installation of process equipment is expected to be finished by the middle of 2002 with validation of this 300,000-unit facility to be completed early in 2003. Once finished, Hemosol will be the first company to have a commercial- scale manufacturing facility to produce hemoglobin based oxygen therapeutics.

About Hemosol Inc.

Hemosol is a near-term, commercial-stage biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range of products in development, including its flagship product Hemolink(TM) (hemoglobin raffimer), an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery to the circulatory system. HEMOLINK is currently being evaluated in late-stage clinical trials. The Company also is developing additional oxygen therapeutics and a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, as well as a cell therapy initially directed to the treatment of cancer through its cell expansion and stem cell research activities.

For more information visit Hemosol`s website at www.hemosol.com.

Hemosol Inc.`s common shares are listed on The NASDAQ Stock Market under the trading symbol ``HMSL`` and on the Toronto Stock Exchange under the trading symbol ``HML``.

Hemolink(TM) is a registered trademark of Hemosol Inc.

Certain statements concerning Hemosol`s future prospects are ``forward- looking statements`` under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol`s ability to obtain regulatory approvals for its products; Hemosol`s ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for Hemosol`s products; the degree of market penetration of Hemosol`s products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.

SOURCE: Hemosol Inc.

[SCARFACE13]

Wednesday March 20, 5:41 pm Eastern Time
Protein Design psoriasis drug fails in tests
(UPDATE: Adds analyst comments, stock price in paras 3-4,7-11)

By Edward Tobin

NEW YORK, March 20 (Reuters) - Protein Design Labs Inc. (NasdaqNM:PDLI - news) on Wednesday said its psoriasis treatment failed to meet its main goal in trials, sending the company`s stock reeling in after-hours trading.
ADVERTISEMENT



The Fremont, California-based firm said Phase II tests of its Zenapax treatment for patients with moderate-to-severe psoriasis following treatment with cyclosporine did not prolong the time to recurrence of psoriasis, the main target of the trial.

Shares of the firm, already well off its 52-week high of $45.46, fell to $13.20 in after-hours trading compared with a close of $15.02 Wednesday on the Nasdaq.

``Clearly, this news is damaging to the stock, at least for near term,`` said Jennifer Chao, an analyst with brokerage firm Leerink Swann & Co., who rates the stock a ``hold.``

Protein Design said it plans to end development of Zenapax as a combination treatment for psoriasis in conjunction with cyclosporine, but could decide to pursue other development options for the drug, known by the chemical name daclizumab, in psoriasis.

``We do plan to continue to explore the use of daclizumab in other indications, and currently there are trials under way in asthma, multiple sclerosis, type I diabetes and uveitis,`` the company said.

``This is certainly a setback, but I do not think it is the end of the world for Protein Design Labs,`` said analyst Michael Wood of Lehman Brothers. ``They have a licensing business which is worth a lot, and an experimental leukemia drug that, while controversial, could be on the market by 2004.``

Recent trial results from a pivotal-stage trial in 191 leukemia patients of the Protein Design experimental drug Zamyl were mixed. The trial failed to show the drug met its goal by improving remission rates within 70 days, but showed that Zamyl boosted patient response to chemotherapy by 65 percent.

Analysts said the next catalyst for Protein Design Labs could be a the American Society for Clinical Oncology meeting in May, where the firm is slated to present additional Phase III Zamyl data.

But Leerink Swann`s Chao said she remains cautious on Zamyl because she does not expect the results will be significantly different than the earlier data.

Zenapax is currently sold by Roche Holding AG for preventing organ rejection in kidney-transplant patients.

[SCARFACE13]

HIER GIBT ES MORGEN AUCH EIN BLUTBAD!!!!!!
HMSL!!!!


Wednesday March 20, 5:58 pm Eastern Time
Canada denies Hemosol blood product application
(UPDATE: Adds comment from analysts)

By Jeffrey Hodgson

TORONTO, March 20 (Reuters) - Hemosol Inc. (Toronto:HML.TO - news)(NasdaqNM:HMSL - news) said on Wednesday that Canadian health authorities had rejected its application to market its Hemolink blood replacement product, a setback analysts said will send its stock lower.
ADVERTISEMENT



The Toronto-based biopharmaceutical company said it was told by Health Canada it must refile the application with additional information. Hemolink is an oxygen therapeutic designed to take the place of donor blood for patients undergoing surgeries.

``In terms of impact on the stock there could very well be negative impact because here`s a Western regulatory agency that has reviewed the data and apparently found it wanting, for one reason or another. We don`t know what the reason is yet,`` said Ezra Lwowski, a senior analyst with Yorkton Securities.

Hemosol said it expects to receive details of Health Canada`s requirements in a letter from the agency.

``We took the initiative to file in Canada first and this has provided us with valuable guidance that will allow us to further the commercialization of Hemolink,`` Hemosol chief executive John Kennedy said in a statement.

``We will evaluate the details of the response from Health Canada when we receive it, and after full consideration, make the appropriate decisions with respect to the priority of a refiling in Canada relative to opportunities for Hemolink in other countries.``

The company said clinical trials designed to meet regulatory approval in the United States and Britain remain on schedule to be completed in the second quarter of 2002.

But a second analyst, who spoke on condition of anonymity, said the Canadian decision was ``a major blow`` and could send their stock down by half.

``They`ve been losing a lot of support, and I think this is going to be kind of the last straw. They`re not in a very solid cash position either. They have about a year of cash. So it`s going to be hard to find reasons to keep holding the stock,`` the analyst said.

Shares of Hemosol plunged 45 percent during one session in August after U.S. regulators asked for changes to the clinical trials of Hemolink.

Hemosol`s stock was up 7 Canadian cents to C$5.88 in Toronto prior to being halted for the news. On Nasdaq the stock was up 4 cents to C$3.74.

($1 equals $1.58 Canadian)

AGGRESSIVE SELL HMSL!!!!!



AL PACINO

[SCARFACE13]

GESTEN ANGEKÜNDIGT
HMSL -29%!!!
AGGRESSIVE SELL HMSL !!!!!!




AL PACINO

[JohnDoo]

RÜLPS!!!!!!!!!!!

[puhvogel]

Boston Scientific Receives FDA Approval For U.S. Clinical Trial of Its Paclitaxel-Eluting Coronary Stent System
NATICK, Mass., March 21 /PRNewswire-FirstCall/ --
Boston Scientific Corporation (NYSE: BSX) announced today that it has received
Investigational Device Exemption (IDE) approval from the U.S. Food and Drug
Administration (FDA) to begin its TAXUS IV clinical trial.
The fourth trial in the TAXUS(TM) drug-eluting stent program, TAXUS IV is
a pivotal study to collect data to support regulatory filings for U.S. product
commercialization. The prospective, randomized, double-blind trial is designed
to assess the safety and efficacy of a slow-release dose formulation
paclitaxel-eluting TAXUS stent system for the treatment of coronary
restenosis. More than 1,000 patients are scheduled to be enrolled at 80
sites.
"This is the green light to begin one of the most important trials in our
company`s history," said Jim Tobin, President and Chief Executive Officer of
Boston Scientific. "I expect TAXUS IV to demonstrate that we have an
effective drug with a durable carrier that provides safe and consistent
release dynamics. We`ve reported excellent results in earlier TAXUS trials,
and we`re optimistic that this trial will provide confirming evidence of the
safety and effectiveness of this innovative therapy."
The TAXUS program is a series of clinical studies designed to collect data
on Boston Scientific`s proprietary paclitaxel-eluting stent technology for
reducing coronary restenosis, the growth of scar tissue within an artery after
angioplasty and stenting. Paclitaxel, the active component of the popular
chemotherapeutic agent Taxol(TM), has demonstrated promising results in pre-
clinical and clinical studies for reducing the processes leading to
restenosis. The comprehensive TAXUS program positions Boston Scientific to
launch paclitaxel-eluting stents in Europe this year and in the U.S. in 2003.
The TAXUS I trial confirmed safety and reported zero thrombosis and zero
restenosis. The TAXUS II trial completed enrollment of 537 patients in
January, and the patients are now in the follow-up period. Preliminary safety
data from TAXUS II presented this week at the American College of Cardiology
annual meeting provided further support for the safety of paclitaxel-eluting
stents. The TAXUS III trial studied the treatment of in-stent restenosis and
also confirmed safety with no thrombosis. The study reported encouraging
efficacy data.
The TAXUS IV trial will use the Express(TM) stent, a laser-cut, balloon-
expandable stent developed exclusively by Boston Scientific.
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices. The Company`s products are used in a broad range of
interventional medical specialties.
This press release contains forward-looking statements. The Company
wishes to caution the reader that actual results may differ from those
discussed in the forward-looking statements and may be adversely affected by,
among other things, risks associated with clinical trials, the regulatory
approval process, physician acceptance of new products, competitive product
offerings and other factors described in the Company`s filings with the
Securities and Exchange Commission.

[@Alle]

Biotechs SELL!!!!!!

Alle neue tiefststände!!!!!












sell!!!!!!!!!!!!!!!!!!!!!!!!!!!

[@Alle]

Die Biotechblase zerplatzt!!!!!!



biotechs sell!!!!!!

[Aeppler]

Du kannst mir mal den Schuh aufblasen.

@eppler

[ZittrigeHand]

@ alle und konsorten

CHTT + 233%
AGIX + 33 % ALTH + 13 %
NUTR + 206%
BPRX + 331%
IMA + 20 %

und so weiter.....
wie man sieht....es gibt auch bios die laufen.

[SCARFACE13]

MORGEN WIRD ES HEFTIG!!!!



Barron`s: Big-cap biotechs overvalued
By Deborah Adamson, CBS.MarketWatch.com
Last Update: 2:14 PM ET April 27, 2002




NEW YORK (CBS.MW) -- Large-cap biotechs may be set for a fall since they`re still too expensive even after a slump in their stocks, according to a Barron`s article Saturday.



The Amex Biotech Index ($BTK: news, chart, profile) has plunged by almost half of its value since its peak in 2000, but it still has rallied by 226 percent over the last five years.

Barron`s took issue with the biggest members of the sector, saying that the top eight are trading at an average of 50 times 2002 earnings -- twice their expected average long-term growth rate of 25 percent and more than double the S&P 500`s multiple.

Large biotechs also don`t show "really strong fundamentals," good visibility and upside revisions to warrant their premium, said Mike Yellen, manager of the AIM Global Health Care Fund (GGHCX: news, chart, profile), whom Barron`s quoted.


FRONT PAGE NEWS
Slogging toward recovery: Now the unglamorous part
WorldCom`s Bernie Ebbers: Debt or Alive?
U.S. stocks suffer worst week since September
Brokers can`t catch a break





Sign up to receive
FREE e-newsletters:






Get the latest news
24 hours a day from our 100-person news team.


Also, some of these companies have been hit with bad news.

The Food and Drug Administration wouldn`t review ImClone Systems` (IMCL: news, chart, profile) application for its cancer drug, Erbitux.

Genentech (DNA: news, chart, profile) and Xoma (XOMA: news, chart, profile) said they would delay their application for psoriasis treatment, Xanelim.

Biogen`s (BGEN: news, chart, profile) multiple-sclerosis treatment, Avonex, could lose market share to a competing drug by Serono, Rebif. Avonex contributes about 90 percent of Biogen`s revenue.

Genzyme (GENZ: news, chart, profile) has been struggling with inventory backlog of Renagel, its kidney dialysis drug.

Even strong companies could be vulnerable, such as Idec Pharmaceuticals (IDPH: news, chart, profile) and Amgen (AMGN: news, chart, profile).

Penetration of Idec`s Rituxan drug, which is used in the treatment of non-Hodgkin`s lymphoma, seems to be peaking in some key markets. Growth could drop as low as 15 percent in 2004. Last year, sales grew by 84 percent.

Thus, Idec`s earnings growth could shrivel to 16 percent in 2004, compared with 44 percent this year.

Idec trades at 64 times its 2002 earnings.

As for Amgen, sales of its second-generation drug Aranesp is starting slowly but business could pick up if it`s approved for use in oncology. Total product sales should increase in the 20 percent range this year, up from a prior forecast of growth in the high teens.

But Amgen faces a big risk in its purchase of rival Immunex (IMNX: news, chart, profile) for $16 billion.

Barron`s said some analysts estimate that Immunex`s rheumatoid arthritis drug Enbrel would have to generate at least $2.5 billion in yearly sales to make the acquisition pay off for Amgen. Last year`s Enbrel sales were $762 million.

However, Enbrel could face competition from Abbott Labs` (ABT: news, chart, profile) D2E7 drug, among others.

Amgen trades at 39 times 2002 earnings. Some analysts speculate that the stock will eventually trade more like big drug stocks -- Amgen and Immunex would have a $74 billion market cap -- which sell for an average 22 times this year`s earnings.

Deborah Adamson is a reporter for CBS.MarketWatch.com in Los Angeles.




AGGRESSIVE SELL ALL BIOTECHS!!!!!




AL PACINO

[@Alle]

sell biotechs!!!!!!!!!!

[guru2002]

Hier gibt es heute auch einen crash!!!!

Monday April 29, 7:01 am Eastern Time
Press Release
SOURCE: NeoTherapeutics, Inc.
NeoTherapeutics Announces Preliminary Results From Clinical Study of Neotrofin(TM) in Alzheimer`s Disease
Company Awaits Results From Additional Studies in Parkinson`s Disease, Spinal Cord Injury and Chemotherapy-Induced Neuropathy
IRVINE, Calif., April 29 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - news) today reported that based on preliminary analysis, some Alzheimer`s patients taking its lead drug Neotrofin experienced improvement in ADAS-cog scores and clinical global change ratings, which were the primary endpoints for the trial, but that overall, these results did not achieve statistical significance favoring Neotrofin over placebo for the pre-determined pivotal 12-week endpoints necessary to meet U.S. Food and Drug Administration requirements for approval in Alzheimer`s disease. The Company is awaiting results from studies of Neotrofin in Parkinson`s disease, spinal cord injury and chemotherapy induced neuropathy, and plans to seek a co-development partner for Neotrofin prior to initiating additional clinical studies of the drug.

"Neotrofin has been shown, in animal models, to be biologically active in neuroprotection, the release of neurotrophic factors and stimulating stem cell proliferation. We are disappointed that the study did not produce statistically significant results at 12 weeks that would support regulatory approval in Alzheimer`s disease," stated Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer of NeoTherapeutics. "We will await further analysis, as well as results from our ongoing phase 2 studies of Neotrofin in other indications and the conclusion of discussions with potential co-development partners, prior to moving forward with additional clinical studies of Neotrofin. Going forward, we will increase our focus on the many exciting opportunities that we have at NeoTherapeutics such as our late-stage anti-cancer drugs, our anti-psychotic platform and our genomics division."

Phase 2 studies of Neotrofin are ongoing in Parkinson`s disease, spinal cord injury and chemotherapy-induced neuropathy. Twenty-eight and thirty-three patients have been enrolled in the Parkinson`s disease and spinal cord injury studies, respectively. The Company expects to complete these studies by year-end. Two studies of Neotrofin in chemotherapy-induced neuropathy were initiated in January of 2002. The results of these trials are anticipated in 2003.

"Over the past 18 months we have embarked on a strategy to broaden our product portfolio and expand the testing of Neotrofin to a variety of neurological indications in 2001," stated Rajesh C. Shrotriya, M.D., President and Chief Operating Officer of NeoTherapeutics. "Our success in licensing in late stage drugs, like satraplatin, and launching studies of Neotrofin in more clear-cut indications, such as chemotherapy induced neuropathy, provide us with attractive opportunities to create value. We plan to hold off on further pursuit of the Alzheimer`s indication until we find a partner. We anticipate that this will reduce our expected burn rate from approximately $2.3 million to less than $1.5 million per month, and will allow our clinical development group to focus their attention on clinical trials of our phase 3 anti-cancer drug, satraplatin."

NeoTherapeutics seeks to create value for stockholders through in-licensing and commercialization of anti-cancer drugs, the discovery and development of central nervous system (CNS) drugs, and the licensing out of new drug targets discovered through genomics research. The Company`s lead oncology drug, satraplatin, is being prepared for a phase 3 study in prostate cancer. Phase 2 studies of Neotrofin(TM) in Parkinson`s disease, spinal cord injury and chemotherapy-induced neuropathy are ongoing. Additional anti-cancer drugs are in phase 1 and 2 human clinical trials, and the Company has a rich pipeline of pre-clinical neurological drug candidates. For additional information visit the Company`s web site at http://www.neot.com.

This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company`s reports filed with the Securities and Exchange Commission.


Contacts:
MEDIA RELATIONS
Jon Siegal
Ronald Trahan Associates (RTA) Inc.
[phone], ext. 15

INVESTOR RELATIONS
John McManus
NeoTherapeutics Inc.
[phone], ext. 247

SOURCE: NeoTherapeutics, Inc.

[KMS]

Billiger wird`s nimmer:

29.04.2002
Amgen "strong buy"
Credit Suisse First Boston

Rating-Update:

Die Analysten vom Investmenthaus Credit Suisse First Boston stufen die Aktie von Amgen (WKN 867900) unverändert mit "strong buy" ein. Die Aranesp-Zulassung in den USA zur Krebsbehandlung könnte im Juli erteilt werden. Bislang habe man mit einer Genehmigung im vierten Quartal gerechnet. In den Jahren 2002 bis 2004 dürften mit Aranesp Umsätze von 365 und 915 Millionen US-Dollar bzw. 1,5 Milliarden US-Dollar erzielt werden.


MfG
KMS

[ceckx]

kms
JA Ja BILLIGER WIRDS NIMMER?????

depp!

[Ariminios]

DAS SIEHT BÖSE AUS!

[SCARFACE13]

ALL BIOTECHS AGGRESSIVE SELL!!!!!!!!



AL PACINO

[Psychozocker.com]

BIOTECH = INERNET !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

[@Alle]

Kommentar vom 21.06.2002

Niedergang der Biotechs

Eine Pleitewelle, wie sie die Frankfurter Allgemeine Sonntagszeitung in ihrer letzten Ausgabe für die Biotech-Branche in Deutschland vorhersagt, wird die am Neuen Markt notierten Gesellschaften kurzfristig nicht treffen, weil aus den IPOs noch genügend Geld vorhanden ist. Mittel- und langfristig sieht es für die Biotech-Werte am Neuen Markt aber düster aus.

Denn die Musik in der Biotechnologie spielt eindeutig in den USA. Firmen wie Amgen, MedImmune, Genentech oder Genzyme verfügen über riesige Kassenbestände und gut gefüllte Produktpipelines, so dass sie ihre Forschungen aus eigenen Einnahmen finanzieren können.

Dagegen sind die deutschen Pendants bei der Umsetzung der kostspieligen Forschungsvorhaben in der Regel auf weitere Mittelzuflüsse aus externen Quellen angewiesen. Nachdem die Euphorie für die Branche aber merklich abgekühlt ist, dürften diese nur schwer aufzutreiben sein.

Internetbranche als Vorbild

Die Entwicklung bei den Biotechnologiewerten wird aller Voraussicht nach ähnlich verlaufen wie bei den Internetwerten: Einem Boom, verbunden mit völlig unrealistischen Wachstumsfantasien, folgen einbrechende Aktienkurse und eine Pleitewelle. Die Branchenkonsolidierung werden vorwiegend Marktführer überleben, die fast ausschließlich in den USA sitzen

[@Alle]

.

[@Alle]

die biotechblase platzt!!!!!
raussssss


SELL!!!!!

[@Alle]

alle biotechs strong sell!!!!!!

[ASICS]

Hey Du Schlaumeier mit wem unterhälst Du dich eigentlich ??